AstraZeneca acquires all rights to Orexo´s OX-CLI project
Uppsala, Sweden – March 17, 2016 – Orexo AB (publ) today announced that AstraZeneca has decided to acquire all rights to the leukotriene C4 synthase inhibitor program (OX-CLI project) for MUSD 5. AstraZeneca established a collaboration with Orexo AB for OX-CLI in 2013 and maintained an option to acquire all rights in the program. As the program has advanced into pre-clinical development with an identified development compound (candidate drug), AstraZeneca has chosen to exercise this option. OX-CLI is directed to develop a novel treatment of respiratory disorders such as asthma and COPD.